Magnetar Financial LLC Has $77.04 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Magnetar Financial LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1,445.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,150 shares of the biopharmaceutical company’s stock after purchasing an additional 101,150 shares during the period. Regeneron Pharmaceuticals accounts for 1.8% of Magnetar Financial LLC’s portfolio, making the stock its 7th biggest position. Magnetar Financial LLC owned approximately 0.10% of Regeneron Pharmaceuticals worth $77,038,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $26,000. Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $39,000. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Larson Financial Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 127.3% during the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 28 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on REGN shares. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $672.36 on Thursday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a 50-day moving average price of $691.62 and a 200 day moving average price of $822.93. The stock has a market capitalization of $73.51 billion, a P/E ratio of 17.56, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.86 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.